Rein Therapeutics publishes LTI-03 presentation, Phase 2 trial enrolling
Rein Therapeutics published an LTI-03 presentation citing Phase 1b biomarker activity, preclinical antifibrotic data and that the RENEW Phase 2 trial is now enrolling.
Rein Therapeutics published a presentation on LTI-03 highlighting Phase 1b biomarker activity, preclinical antifibrotic data and that the RENEW Phase 2 trial is now enrolling.Key Highlights:Original SEC Filing: Rein Therapeutics, Inc. [ RNTX ] - 8-K - Sep.
04, 2026This is an AI-powered summary.
It…